A type of dermal dermal papilla cell and its application

By constructing dihydrotestosterone-resistant human dermal papillary cells, the problems of unstable and easily damaged cell models in existing technologies have been solved, enabling in-depth research and improvement of hair regeneration efficacy, while reducing drug development costs.

CN123063337APending Publication Date: 2026-11-10MEICHUANG ZHIYAN TECHNOLOGY (HANGZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611380839.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-07
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies make it difficult to construct stable human dermal papillary cell models for the research and treatment of androgenetic alopecia, and transplanted cells are susceptible to damage from dihydrotestosterone, affecting hair regeneration.

Method used

We constructed dihydrotestosterone-resistant human dermal papillary cells (DPCs) as a stable model for in-depth research on the DHT damage mechanism, and as high-quality seed cells for cell transplantation therapy, establishing a high-throughput drug screening platform.

Benefits of technology

It provides a stable cell model for in-depth research on the DHT damage mechanism, improves the efficacy of hair regeneration, reduces the cost and cycle of anti-hair loss drug development, and solves the problem that cells are easily inhibited by the internal androgen environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates to a dermal dermal papilla cell and its application, wherein the dermal dermal papilla cell exhibits DHT resistance. The construction of DHT-resistant dermal dermal papilla cells is of groundbreaking significance for the research and treatment of androgenetic alopecia (AGA). It can also be used for efficient screening of anti-DHT and hair follicle-promoting drugs, replacing traditional cumbersome models, reducing research and development costs, and providing support for the development of novel therapeutic drugs for AGA. It has significant theoretical and practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of cell technology, specifically relating to a dermal dermal papilla cell and its application. Background Technology

[0002] Androgenetic alopecia (AGA) is a very common progressive hair loss disease in clinical practice. Its core pathological feature is follicle miniaturization, where terminal hairs gradually degenerate into fine, soft vellus hairs, eventually leading to thinning or even hair loss. This process is mainly regulated by both genetic factors and androgens, with dihydrotestosterone (DHT) being recognized as a key pathogenic factor in AGA. Under the action of 5α-reductase, testosterone is converted into DHT, which then attacks hair follicles carrying androgen receptors, leading to disordered hair follicle growth cycles, shortened anagen phase, and prolonged telogen phase.

[0003] Human dermal papillary cells (DPCs) are located at the base of hair follicles and regulate hair follicle growth, development, and cyclical processes. DPCs maintain the activity of hair follicle stem cells and induce hair regeneration by secreting various growth factors and cytokines. However, in the pathological environment of AGA (Advanced Geriatric Alopecia Areata), high levels of DHT directly act on DPCs, inducing the cells to produce excessive reactive oxygen species (ROS), which in turn activate inhibitory signaling pathways such as TGF-β1. This pathological change not only leads to impaired DPC function and abnormal secretory lineage but also induces cellular senescence and apoptosis, ultimately causing hair follicles to gradually atrophy due to loss of growth signal support.

[0004] While current treatments for AGA (such as topical minoxidil and oral finasteride) can slow down hair loss to some extent, they still have limitations. In basic research, the lack of stable cell models that can resist DHT damage makes it difficult for researchers to observe the specific damage mechanisms of DHT on DPCs and the effects of drug interventions in vitro in a long-term and stable manner. Traditional animal models or primary cell cultures often suffer from short cycles, large individual differences, or susceptibility to inactivation due to hormonal influences. In clinical applications, although hair follicle transplantation and cell therapy are considered effective treatments for hair loss, transplanted DPCs exposed to high concentrations of DHT are highly susceptible to further damage and loss of activity, leading to secondary hair loss after the initial treatment and severely impacting the long-term efficacy of hair regeneration.

[0005] Therefore, constructing a human dermal papillary cell (DPC) line that can tolerate DHT damage and maintain stable biological activity has become an urgent need in the current field of hair loss research. Summary of the Invention

[0006] To address at least one of the aforementioned problems, the present invention provides dermal papilla cells and their applications.

[0007] According to one aspect of the present invention, dermal dermal papilla cells are provided, said dermal dermal papilla cells having DHT resistance.

[0008] Preferably, the cells were deposited on June 23, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 46860.

[0009] According to another aspect of the invention, the application of the aforementioned dermal papilla cells in the construction of animal models is provided.

[0010] Preferably, the animal is a non-human mammal.

[0011] Preferably, the animals include one or more of non-human primates, livestock, domestic animals, and laboratory animals; Preferably, the non-human primates include one or more of chimpanzees, apes, and monkeys; Preferably, the livestock includes one or more of cattle, horses, sheep, goats, and pigs; Preferably, the livestock includes one or more of rabbits, dogs, and cats; Preferably, the laboratory animals include rodents; Preferably, the rodents include one or more of rats, mice, and guinea pigs.

[0012] Preferably, the animal model is used for one or more of the following: 1) Screening for drugs for the prevention or treatment of hair loss, anti-DHT, and promotion of skin appendage regeneration, or one or more of these. 2) Screening reagents for diagnosing or detecting hair loss; 3) Research on the targets, etiology, development mechanism, and pathogenesis of hair loss drugs.

[0013] Preferably, the skin appendages include one or more of hair follicles, sebaceous glands, and sweat glands.

[0014] Preferably, the hair loss includes one or more of the following: androgenetic alopecia, alopecia areata, telogen effluvium, scarring alopecia, drug-induced alopecia, disease-related alopecia, and nutritional alopecia.

[0015] Preferably, the hair loss is androgenetic alopecia.

[0016] According to another aspect of the invention, an animal model constructed from the aforementioned dermal dermal papilla cells is provided.

[0017] Compared with the prior art, the present invention has at least the following beneficial technical effects: This invention successfully constructed dihydrotestosterone (DHT)-resistant human dermal papillary cells (DPCs), which is of great significance for the research and treatment of androgenetic alopecia (AGA). DHT, a key factor leading to AGA, damages DPC function, induces cell senescence and apoptosis, and subsequently causes hair follicle miniaturization. As the core regulatory cells for hair follicle growth, the stable function of DPCs is crucial for hair regeneration. At the basic research level, this cell line can serve as a stable model to further explore the mechanisms of DHT damage to DPCs, such as ROS-mediated abnormal TGF-β1 secretion pathways. In clinical applications, it provides an ideal cell source for cell transplantation therapy for AGA, avoiding post-transplant cell damage by DHT and improving the efficacy of hair regeneration treatment.

[0018] In addition, this cell line can be used to efficiently screen drugs that resist DHT and promote hair follicle growth, replacing traditional cumbersome models, reducing research and development costs, providing support for the development of AGA therapeutic drugs, and providing a reference for the research of related skin diseases, which has important theoretical and practical application value. Attached Figure Description

[0019] Figure 1 The dose-response curve of DHT inhibiting hDPC cell viability is shown.

[0020] Figure 2 The expression levels of hDPC characteristic markers are shown.

[0021] Figure 3 The expression of CD133 on the surface of hDPC was detected by flow cytometry.

[0022] Figure 4 Cell proliferation curves at different DHT treatment concentrations are shown.

[0023] Figure 5 The levels of VEGF secretion under different DHT treatment concentrations are shown.

[0024] Figure 6 The levels of IGF-1 secreted under different DHT treatment concentrations are shown.

[0025] Figure 7 The amount of KGF secreted under different DHT treatment concentrations is shown.

[0026] Figure 8 The levels of TGF-β secreted under different DHT treatment concentrations are shown.

[0027] Figure 9 The results of the Western blot experiment are shown.

[0028] Figure 10 The results show the effects of screening and passage culture on IGF-1 secretion in hDPC cells.

[0029] Figure 11 The results show the effects of screening and passage culture on KGF secretion in hDPC cells.

[0030] Figure 12 The results show the effects of screening and passage culture on TGF-β secretion in hDPC cells.

[0031] Figure 13 The results show the effects of screening and passage culture on VEGF secretion in hDPC cells.

[0032] Figure 14 The results show the effect of DHT treatment on the proliferation of hDPC cells at different screening and passage stages.

[0033] Figure 15 The results show the effect of DHT treatment on the cell viability of different cell clones.

[0034] Figure 16 The study showed the amount of IGF-1 secreted by hDPC-DR compared to hDPC after DHT treatment.

[0035] Figure 17 The study showed the amount of KGF secreted by hDPC-DR compared to hDPC after DHT treatment.

[0036] Figure 18 The study showed the secretion of TGF-β by hDPC-DR compared to hDPC after DHT treatment.

[0037] Figure 19 The study showed the VEGF secretion levels of hDPC-DR compared to hDPC after DHT treatment.

[0038] Figure 20 The growth curves of hDPC-DR versus hDPC after DHT treatment are shown.

[0039] Figure 21 The morphology of hDPC compared to hDPC-DR under a microscope is shown.

[0040] Figure 22 A volcano plot of differentially expressed genes between hDPC and hDPC-DR is shown.

[0041] Figure 23 The results of KEGG enrichment analysis of differentially expressed genes between hDPC and hDPC-DR are shown. Detailed Implementation

[0042] This invention provides a dermal dermal papilla cell line and its applications. This cell line not only serves as an ideal in vitro model for in-depth analysis of DHT-mediated ROS-TGF-β1 and other damage pathways, filling a gap in the study of AGA pathological mechanisms, but also as a high-quality seed cell source for cell transplantation therapy, fundamentally solving the problem of transplanted cells being easily suppressed by the androgen environment in the body. Furthermore, the high-throughput drug screening platform established based on this drug-resistant cell line will significantly reduce the cost and cycle of anti-hair loss drug development, possessing significant scientific value and promising clinical application prospects.

[0043] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be described in detail below with reference to specific embodiments. The specific embodiments described herein are for illustrative purposes only and are not intended to limit the invention in any way. Furthermore, descriptions of well-known structures and techniques are omitted in the following description to avoid unnecessarily obscuring the concept of the invention. Such structures and techniques have also been described in many publications.

[0044] definition Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly used in the field to which this invention pertains. For the purposes of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural forms, and vice versa.

[0045] In this invention, the terms "about", "approximately", or "approximately" generally refer to within 20%, 10%, 5%, 4%, 3%, 2%, or 1% of a given value or range. Unless otherwise specified, the quantities given are approximate values, implying that the terms "about", "approximately", or "approximately" can be derived from them.

[0046] Unless the context clearly indicates otherwise, the terms “a” and “an” as used herein include plural references.

[0047] The following embodiments and accompanying drawings are provided to aid in understanding the present invention. However, it should be understood that these embodiments and drawings are for illustrative purposes only and do not constitute any limitation. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.

[0048] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be described in detail below with reference to specific embodiments. The specific embodiments described herein are for illustrative purposes only and are not intended to limit the invention in any way. Furthermore, descriptions of well-known structures and techniques are omitted in the following description to avoid unnecessarily obscuring the concept of the invention. Such structures and techniques have also been described in many publications.

[0049] The following embodiments and accompanying drawings are provided to aid in understanding the present invention. However, it should be understood that these embodiments and drawings are for illustrative purposes only and do not constitute any limitation. The actual scope of protection of the present invention is set forth in the claims. It should be understood that any modifications and changes can be made without departing from the spirit of the present invention.

[0050] Example 1: Performance Testing of Original Samples The original sample was commercially purchased immortalized human dermal papilla cells (catalog number: FH-Y052, Shanghai Fuheng Biotechnology Co., Ltd.), denoted as human dermal papilla immortalized cells hDPC.

[0051] (1) IC50 (half-maximal inhibitory concentration) detection The IC50 (half-maximal inhibitory concentration) of human dermal papillary immortalized cells (hDPC) was detected using the CCK-8 kit (Cell Counting Kit-8, Beyotime, catalog number C0038).

[0052] The dose-response curve of DHT inhibiting hDPC cell viability is as follows: Figure 1 As shown in the figure. The measurement results show that the 48-hour IC50 of this hDPC is higher than that of the 72-hour IC50. Meanwhile, the 48-hour IC50 of the untreated hDPC is around 4.57 μM, which is on the order of 1 μM as expected.

[0053] (2) Detection of characteristic markers Western blot was used to detect the expression levels of hDPC characteristic markers. The primary antibodies used were Versican antibody (Wuhan Sanying, 14395-1-AP), α-SMA antibody (Wuhan Sanying, 30599-1-AP), and internal control GAPDH antibody (Wuhan Sanying, HRP-60004). The secondary antibody was Multi-rAb® HRP-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L). The steps are as follows: Protein sample preparation and quantification: Collect the samples to be tested, extract total protein using protein lysis buffer, collect the supernatant by centrifugation, determine the protein concentration using a protein quantification kit, standardize the protein loading amount for each group of samples, add loading buffer, denature in boiling water bath for 5-10 min, and cool for later use.

[0054] SDS-PAGE gel electrophoresis: Prepare separating gel and stacking gel, add the denatured protein sample to the gel loading wells, perform low-voltage constant voltage electrophoresis first, and after the sample enters the separating gel, increase the voltage. Stop electrophoresis when the molecular weight region corresponding to the target protein is fully separated.

[0055] Transfer: Remove the gel after electrophoresis, assemble the transfer jacket in the order of filter paper-gel-PVDF membrane-filter paper, remove air bubbles throughout the process, place it in the transfer apparatus, and perform constant current / constant pressure wet transfer to transfer the protein on the gel to the PVDF membrane.

[0056] Blocking: After the transfer is complete, remove the PVDF membrane and place it in the blocking solution. Block at room temperature for 1-2 hours to block non-specific binding sites on the membrane. After blocking, wash the membrane 3 times with washing solution for 5 minutes each time.

[0057] Antibody incubation: Immerse the washed PVDF membrane in diluted primary antibody working solution and incubate overnight at 4°C. After incubation, discard the primary antibody solution and wash the membrane thoroughly 3 times with washing buffer for 5-10 minutes each time. Then add diluted horseradish peroxidase-labeled secondary antibody working solution and incubate at room temperature in the dark for 1 hour. After incubation, wash the membrane 3 times again to remove residual secondary antibody.

[0058] Step 6: Color development and detection analysis: Add chemiluminescent color development solution to the cleaned PVDF membrane, allow it to react fully in the dark, and then place it in a gel imaging system to acquire luminescent images. Detect the gray value of the target protein band and use the internal reference protein as a reference to analyze the relative expression level of the target protein in each group of samples.

[0059] The results are as follows Figure 2 As shown, the antibodies Versican and α-SMA exhibit high expression in the 2nd, 4th, and 8th generation hDPCs, with expression levels higher than those in human skin fibroblasts (HSF).

[0060] The expression of CD133 on the surface of hDPCs was detected by flow cytometry. Negative controls were performed using hSF cells (human skin fibroblasts, catalog number: STM-CL-5176, brand: Stemer). Results are as follows: Figure 3 As shown, flow cytometry results for hsf showed that it was CD133 negative. Passage culture of hDPC cells showed that the 2nd, 4th, and 8th generations were all CD133 positive, indicating that CD133 is persistently highly expressed and that this trait is stably inherited.

[0061] Example 2 Screening for drug-resistant hDPC (1) Determination of initial concentration Cell proliferation at different DHT concentrations was determined using a CCK-8 assay kit. The test concentrations were 0.3x, 0.5x, 0.7x, and 0.9x IC50. The results are as follows: Figure 4 As shown, 0.5 times IC50 was selected as the optimal starting concentration for pressure screening (maximum concentration with minimal impact on cell growth and function).

[0062] Subsequently, hDPC cells were cultured continuously for 2-3 weeks. The growth factor secretion function of hDPC cells at different DHT concentrations (0.3x IC50, 0.5x IC50, 0.7x IC50, and 0.9x IC50) was detected using ELISA. The corresponding detection kits were used for each: VEGF: Human VEGF ELISA Kit (ELISA), Lianke Biotechnology; IGF-1: Human IGF-1 ELISA Kit (ELISA), Lianke Biotechnology; KGF: Human KGF / FGF-7 ELISA Kit (ELISA), Lianke Biotechnology; TGFβ: Human / Mouse TGF-β1 ELISA Kit (ELISA), Lianke Biotechnology. The results are as follows: Figure 5-8 As shown, it can be seen that VEGF (vascular endothelial growth factor) Figure 5 IGF-1 (insulin-like growth factor-1) Figure 6 KGF (keratinocyte growth factor), Figure 7 ) and TGF-β (transforming growth factor β, Figure 8 In the content test, the levels of the four cytokines in hDPC at 0.5 times IC50 concentration showed a similar trend to the results of the Western blot experiment. Figure 9 Therefore, 0.5 times IC50 was selected as the starting concentration for pressure screening.

[0063] (2) Gradient screening Starting with a DHT concentration of 0.5 times the IC50, the concentration was increased by 0.1 times the IC50 each time. Cell growth was observed after 2-3 weeks of culture. Once cells achieved stable proliferation at the current concentration, the concentration was increased to the next level, with a final concentration of 1.5 times the IC50. Thereafter, the concentration was not increased further. Cells that proliferated stably at this concentration were passaged, and the levels of VEGF, IGF-1, KGF, and TGF-β in the cell population were measured using standard methods for up to 5 passages and after 15 passages. The specific steps are as follows: When the cell confluence reaches 80%–90%, the cells can be passaged. Warm the culture medium, PBS, and trypsin beforehand, and perform the entire process under aseptic conditions. Discard the old culture medium and wash the cells 1–2 times with sterile PBS to remove residual serum. Add an appropriate amount of trypsin and digest at room temperature / incubator. When cells appear wrinkled and rounded under a microscope, and a small number detach, immediately add complete culture medium to stop the digestion.

[0064] Gently agitate the bottle walls to prepare a single-cell suspension, then dispense it into new culture containers at a 1:3 ratio, adding fresh culture medium. Label the cells with their name, passage number, and date, and incubate at 37°C in a 5% CO2 incubator.

[0065] The results are as follows Figure 10-13 As shown ( Figure 10 For IGF-1, Figure 11 For KGF, Figure 12 For TGF-β, Figure 13 (as of VEGF), it can be seen that the dominant cell population selected at 1.5 times the IC50 concentration did not show significant differences in proliferation rate and growth factor secretion function compared to hDPC cells without concentration selection, and could be stably passaged for more than 15 generations.

[0066] Meanwhile, comparing the growth curves of cells before and after selection revealed that treatment with 0.5 times the IC50 DHT significantly inhibited cell proliferation before selection, while the selected cells maintained resistance to DHT even after 15 passages, and their cell proliferation was not affected by DHT treatment. Figure 14 ).

[0067] (3) Monoclonal screening Monoclonal screening was performed using the limiting dilution cloning (LDC) method. Specifically, the dominant cell population selected by gradient screening was serially diluted to an appropriate concentration and seeded into 96-well plates, ensuring that each well contained only a single cell. The plates were then incubated at 37°C in a 5% CO2 incubator. After monoclonal cell aggregates formed in the wells, monoclonal cell lines with good growth status were selected and expanded for later use.

[0068] A total of 5 single clones were screened and named 1 to 5 respectively. Their IC50 was detected, and the results are as follows: Figure 15 As shown, the IC50 values ​​of monoclonal antibodies 1-5 were all higher than those of hDPC, with monoclonal antibody 5 exhibiting the highest IC50. This monoclonal antibody was named hDPC-DR. The results of the secretion levels of various growth factors in hDPC-DR are as follows: Figure 16-19 As shown ( Figure 16 For IGF-1, Figure 17 For KGF, Figure 18 For TGF-β, Figure 19As can be seen from VEGF), the growth factor secretion level and proliferation rate of hDPC-DR are related to... Figure 8-11 The results for hDPC were largely consistent, and the addition of an IC50 dose of DHT did not significantly change any of the indicators for hDPC-DR, demonstrating that hDPC-DR is resistant to DHT. Comparing the growth curves of the two cell types, the results showed that the proliferation of hDPC cells could be inhibited by DHT, while the proliferation of hDPC-DR was unaffected by DHT. Figure 20 As shown.

[0069] Example 3: Morphological observation and STR identification of hDPC-DR (1) Morphological observation Morphological observation of hDPC cells and hDPC-DR cells under a Leica (DMI8) microscope (200×), such as... Figure 21 The results showed that hDPC-DR cells were typically spindle-shaped with clear cell outlines, strong edge refractive properties, and bright reflections in the center of the cell body (nucleus region). A small number of cells were slightly round / high-brightness, which were likely cells in the mitotic phase or newly adhered to the cell wall.

[0070] (2) STR identification The hDPC cells obtained in Example 1 were subjected to STR identification with hDPC-DR. The results showed that the matching degree between hDPC-DR and hDPC was 100%. The results of sample locus reporter value analysis are shown in Table 1.

[0071] Table 1

[0072] Example 4 Single-cell transcriptome sequencing analysis Three separately cultured hDPC-DR and hDPC cell lines were subjected to transcriptome sequencing. Differentially expressed genes were analyzed using KEGG, and pathways potentially associated with DHT resistance were selected from the results.

[0073] 1) Expression difference analysis After obtaining the Read Counts of genes, differential gene expression analysis was performed between samples to identify differentially expressed genes, and then the functions of these differentially expressed genes were studied. The software used for differential expression analysis was DESeq2, and the default screening criteria for significantly differentially expressed genes were as follows: If FDR < 0.05 and |log2FC| ≧ 1, then a gene is considered a differentially expressed gene (DEG) when both conditions are met.

[0074] 2) GO and KEGG annotation analysis of differentially expressed genes Genes can be classified using the GO database according to the biological processes (BP) they participate in, the cellular components (CC) they constitute, and the molecular functions they perform (MF). GO annotation is then performed on differentially expressed genes. Similarly, genes can be classified using the KEGG database according to the pathways they participate in or the functions they perform. KEGG annotation is then performed on differentially expressed genes.

[0075] ID mapping (KEGG) 3) Differential gene GO and KEGG enrichment analysis Enrichment analysis typically analyzes whether a group of genes has appeared at a specific functional node. Its principle evolved from annotation analysis of single genes to annotation analysis of gene sets. Enrichment analysis improves the reliability of research and can identify the biological processes most relevant to biological phenomena.

[0076] Enrichment analysis was performed using the Goatools software, employing Fisher's exact test. To control for the calculated false positive rate, four multiple tests (Bonferroni, Holm, Sidak, and false discovery rate) were used to correct the p-values. Generally, a corrected p-value (p_fdr) ≤ 0.05 was considered to indicate significant enrichment of the GO function.

[0077] KEGGpathway enrichment analysis was performed using KOBAS (http: / / kobas.cbi.pku.edu.cn / home.do). The calculation principle was the same as that of GO functional enrichment analysis, and Fisher's exact test was used for calculation. To control the false positive rate, the BH (FDR) method was used for multiple tests. The corrected p-value was set with a threshold of 0.05. KEGG pathways that met this condition were defined as KEGG pathways significantly enriched in differentially expressed genes.

[0078] The results are as follows Figure 22-23 As shown, the differentially expressed genes between hDPC-DR and hDPC were enriched in multiple pathways related to DHT resistance, including the hsa04915 androgen and estrogen metabolism pathway, the hsa04350 TGF-β signaling pathway, and the hsa04310 Wnt signaling pathway. These results confirm at the gene level the successful screening of a DHT-resistant hDPC-DR cell line.

[0079] Example 5: Preservation of Cell Lines The selected DHT-resistant hDPC-DR cell line was named MCZY-DPC-A-0001. It belongs to the dihydrotestosterone-resistant human dermal papilla cells and was deposited on June 23, 2026, at the China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46860.

[0080] The technical solutions of the present invention are not limited to the specific embodiments described above. Any technical modifications made in accordance with the technical solutions of the present invention fall within the protection scope of the present invention.

Claims

1. Dermal dermal papilla cells, characterized in that, The dermal papilla cells are DHT resistant.

2. The dermal dermal papilla cells according to claim 1, characterized in that, The cells were deposited on June 23, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 46860.

3. The use of dermal papilla cells as described in any one of claims 1-2 in the construction of animal models.

4. The application according to claim 3, characterized in that, The animal in question is a non-human mammal.

5. The application according to claim 3, characterized in that, The animals include one or more of the following: non-human primates, agricultural animals, livestock, and laboratory animals.

6. The application according to claim 3, characterized in that, The animal model is used for one or more of the following: 1) Screening for drugs for the prevention or treatment of hair loss, anti-DHT, and promotion of skin appendage regeneration, or one or more of these. 2) Screening reagents for diagnosing or detecting hair loss; 3) Research on the targets, etiology, development mechanism, and pathogenesis of hair loss drugs.

7. The application according to claim 6, characterized in that, The skin appendages include one or more of hair follicles, sebaceous glands, and sweat glands.

8. The application according to claim 6, characterized in that, The hair loss includes one or more of the following: androgenetic alopecia, alopecia areata, telogen effluvium, scarring alopecia, drug-induced alopecia, disease-related alopecia, and nutritional alopecia.

9. The application according to claim 6, characterized in that, The hair loss described is androgenetic alopecia.

10. An animal model constructed from dermal dermal papilla cells as described in any one of claims 1-2.